Literature DB >> 15379729

Macrolide resistance from the ribosome perspective.

F Franceschi1, Z Kanyo, E C Sherer, J Sutcliffe.   

Abstract

Macrolides are important antibiotics used in treatment of respiratory tract infections in humans. Although some of these compounds have been in use for 50 years, it has not been until the last few years that their mechanism of action and the nature of ribosomal-based resistance could be more fully understood. With the advent of robust crystals of ribosomal 50S subunits, and structural resolution of macrolides and ketolides complexed to either Haloarcula marismortui or Deinococcus radiodurans 50S, the ability to dissect the binding modes and understand resistance at the level of the ribosome became possible. This review article compares the binding features of 14-, 15-, and 16-membered macrolides to that of ketolides telithromycin and ABT-773 as revealed at the atomistic level. Attempts to understand how modifications to 23S rRNA and/or mutations in ribosomal proteins L4 and L22 that have been found to confer resistance in Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae are told from the perspective of the ribosome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379729     DOI: 10.2174/1568005043340740

Source DB:  PubMed          Journal:  Curr Drug Targets Infect Disord        ISSN: 1568-0053


  20 in total

1.  Revisiting the structures of several antibiotics bound to the bacterial ribosome.

Authors:  David Bulkley; C Axel Innis; Gregor Blaha; Thomas A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

2.  Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event.

Authors:  Daniel R Gentry; David J Holmes
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

3.  Effects on translation pausing of alterations in protein and RNA components of the ribosome exit tunnel.

Authors:  Marlon G Lawrence; Lasse Lindahl; Janice M Zengel
Journal:  J Bacteriol       Date:  2008-06-27       Impact factor: 3.490

4.  The molecular epidemiology of Treponema pallidum subspecies pallidum.

Authors:  Daphne Y Ma; Lorenzo Giacani; Arturo Centurión-Lara
Journal:  Sex Health       Date:  2015-04       Impact factor: 2.706

Review 5.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

6.  Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States.

Authors:  Paulina A Hawkins; Sopio Chochua; Delois Jackson; Bernard Beall; Lesley McGee
Journal:  Microb Drug Resist       Date:  2014-08-12       Impact factor: 3.431

7.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 8.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

9.  A ribosome-nascent chain sensor of membrane protein biogenesis in Bacillus subtilis.

Authors:  Shinobu Chiba; Anne Lamsa; Kit Pogliano
Journal:  EMBO J       Date:  2009-09-24       Impact factor: 11.598

10.  Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid.

Authors:  Seok-Ming Toh; Liqun Xiong; Cesar A Arias; Maria V Villegas; Karen Lolans; John Quinn; Alexander S Mankin
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.